Ran Mo

China Pharmaceutical University 
"Ran Mo"
Mean distance: (not calculated yet)


Sign in to add mentor
Zhen Gu post-doc 2012-2014 NCSU (Neurotree)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Liu H, Liu M, Zhao Y, et al. (2023) Nanomedicine strategies to counteract cancer stemness and chemoresistance. Exploration of Targeted Anti-Tumor Therapy. 4: 630-656
Shen S, Li T, Fan J, et al. (2022) Lipid-polymer hybrid nanoparticle with cell-distinct drug release for treatment of stemness-derived resistant tumor. Acta Pharmaceutica Sinica. B. 13: 1262-1273
Wang Q, Chen C, Xu X, et al. (2022) APAF1-Binding Long Noncoding RNA Promotes Tumor Growth and Multidrug Resistance in Gastric Cancer by Blocking Apoptosome Assembly. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). e2201889
Shen S, Lin S, Chen Y, et al. (2022) Combating Cancer Stem-Like Cell-Derived Resistance to Anticancer Protein by Liposome-Mediated Acclimatization Strategy. Nano Letters
Jiang T, Ma Y, Xu X, et al. (2021) Enzyme-instructed hybrid nanogel/nanofiber oligopeptide hydrogel for localized protein delivery. Acta Pharmaceutica Sinica. B. 11: 2070-2079
Shen S, Xu X, Lin S, et al. (2021) A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells. Nature Nanotechnology. 16: 104-113
Xu X, Huang X, Zhang Y, et al. (2020) Self-regulated hirudin delivery for anticoagulant therapy. Science Advances. 6
Dong H, Xu X, Wang L, et al. (2020) Advances in living cell-based anticancer therapeutics. Biomaterials Science
Wang H, Xu X, Guan X, et al. (2020) Liposomal 9-Aminoacridine for Treatment of Ischemic Stroke: From Drug Discovery to Drug Delivery. Nano Letters
Xu X, Li T, Shen S, et al. (2019) Advances in Engineering Cells for Cancer Immunotherapy. Theranostics. 9: 7889-7905
See more...